CNW.F CO.DON AG INH. O.N.
- Market cap
- EUR 134K
- P/E
- -
- P/B
- 0.16x
- ROE
- -53.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2021.
Is CNW.F undervalued?
Graham numberThe Graham number of CO.DON AG INH. O.N. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CO.DON AG INH. O.N. fundamental analysis
No fundamental analysis for CO.DON AG INH. O.N. yet.
CO.DON AG INH. O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CO.DON AG INH. O.N.
co.don AG does not have significant operations. Previously, the company was engaged in the development, production, and marketing of biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
Full company profileCO.DON AG INH. O.N. financial statements
CO.DON AG INH. O.N. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 |
|---|---|
| Income Statement | |
| Revenue | 9.80M |
| Gross Profit | 9.26M |
| Operating Income | -8.43M |
| EBITDA | -7.03M |
| Net Income | -9.32M |
| EPS | -0.35 |
| Balance Sheet | |
| Total Assets | 26.3M |
| Total Liabilities | 8.75M |
| Shareholders' Equity | 17.6M |
| Cash & Short-term Investments | 6.54M |
| Cash Flow | |
| Operating Cash Flow | -7.95M |
| Capital Expenditure | 498K |
| Free Cash Flow | -8.45M |
| Ratios | |
| ROE | -53.1% |
| ROA | -35.4% |
| Net Profit Margin | -95.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CO.DON AG INH. O.N. dividends
CO.DON AG INH. O.N. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:2 on Aug 19, 2021.
Who owns CO.DON AG INH. O.N.
- Insiders 64.20%
- Institutions 0.00%
- Public & others 35.80%
- Shares outstanding 26.7M
- Free float 25.2M
CO.DON AG INH. O.N. company profile
- Company name
- CO.DON AG INH. O.N.
- Ticker
- CNW.F
- ISIN
- DE000A3E5C08
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Fiscal year end
- December
- Address
- Warthestrasse 21, Teltow, Germany, 14513
- Phone
- 49 3328 43 46 0
- Website
- codon.de
About CO.DON AG INH. O.N.
co.don AG does not have significant operations. Previously, the company was engaged in the development, production, and marketing of biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
CO.DON AG INH. O.N. management
7- Dr. Ying ZhouManaging Director
- Mr. Tilmann BurMember of Executive Board · born 1965
- Mr. Matthias Meissner M.A.Director of Corporate Communications, Investor Relations & Public Relations
- Ms. Anne KemmerichHead of Human Resources
- Dr. Giulietta RoëlHead of Production
- Ms. Karen KühnertHead of Finance
- Dr. Franziska MenzelHead of Regulatory Affairs & Clinical Development